134 related articles for article (PubMed ID: 29605994)
1. Slow Off-Rate Modified Aptamer (SOMAmer) as a Novel Reagent in Immunoassay Development for Accurate Soluble Glypican-3 Quantification in Clinical Samples.
Duo J; Chiriac C; Huang RY; Mehl J; Chen G; Tymiak A; Sabbatini P; Pillutla R; Zhang Y
Anal Chem; 2018 Apr; 90(8):5162-5170. PubMed ID: 29605994
[TBL] [Abstract][Full Text] [Related]
2. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
[TBL] [Abstract][Full Text] [Related]
3. Rapid Slow Off-Rate Modified Aptamer (SOMAmer)-Based Detection of C-Reactive Protein Using Isotachophoresis and an Ionic Spacer.
Eid C; Palko JW; Katilius E; Santiago JG
Anal Chem; 2015 Jul; 87(13):6736-43. PubMed ID: 26024067
[TBL] [Abstract][Full Text] [Related]
4. Developing slow-off dickkopf-1 aptamers for early-diagnosis of hepatocellular carcinoma.
Zhou Y; Li W; Tseng Y; Zhang J; Liu J
Talanta; 2019 Mar; 194():422-429. PubMed ID: 30609553
[TBL] [Abstract][Full Text] [Related]
5. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3.
Xie C; Tiede C; Zhang X; Wang C; Li Z; Xu X; McPherson MJ; Tomlinson DC; Xu W
Sci Rep; 2017 Aug; 7(1):9608. PubMed ID: 28852111
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of Slow Off-Rate Modified Aptamers Reagents in Single Molecule Array Assays for Cytokine Detection with Ultrahigh Sensitivity.
Wu D; Katilius E; Olivas E; Dumont Milutinovic M; Walt DR
Anal Chem; 2016 Sep; 88(17):8385-9. PubMed ID: 27529794
[TBL] [Abstract][Full Text] [Related]
7. Polyclonal antibody production against rGPC3 and their application in diagnosis of hepatocellular carcinoma.
Wang S; Kalim M; Liang K; Zhan J
Prep Biochem Biotechnol; 2018 May; 48(5):435-445. PubMed ID: 29561231
[TBL] [Abstract][Full Text] [Related]
8. Targeting Unique Epitopes on Highly Similar Proteins GDF-11 and GDF-8 with Modified DNA Aptamers.
Ochsner UA; Green LS; Rice TP; Olivas E; Janjic N; Katilius E
Biochemistry; 2019 Nov; 58(46):4632-4640. PubMed ID: 31638376
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe.
Han HH; Qiu YJ; Shi YY; Wen W; He XP; Dong LW; Tan YX; Long YT; Tian H; Wang HY
Theranostics; 2018; 8(12):3268-3274. PubMed ID: 29930728
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
11. Development and Characterization of an HPV Type-16 Specific Modified DNA Aptamer for the Improvement of Potency Assays.
Trausch JJ; Shank-Retzlaff M; Verch T
Anal Chem; 2017 Mar; 89(6):3554-3561. PubMed ID: 28233502
[TBL] [Abstract][Full Text] [Related]
12. Beyond antibodies: new affinity reagents to unlock the proteome.
Lollo B; Steele F; Gold L
Proteomics; 2014 Mar; 14(6):638-44. PubMed ID: 24395722
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma.
Honsová E; Lodererová A; Franková S; Oliverius M; Trunecka P
Cas Lek Cesk; 2011; 150(1):37-40. PubMed ID: 21400962
[TBL] [Abstract][Full Text] [Related]
14. Systematic selection of modified aptamer pairs for diagnostic sandwich assays.
Ochsner UA; Green LS; Gold L; Janjic N
Biotechniques; 2014; 56(3):125-8, 130, 132-3. PubMed ID: 24641476
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
Wang FH; Yip YC; Zhang M; Vong HT; Chan KI; Wai KC; Wen JM
J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450
[TBL] [Abstract][Full Text] [Related]
17. Discovery and diagnostic value of a novel oncofetal protein: glypican 3.
Wang SK; Zynger DL; Hes O; Yang XJ
Adv Anat Pathol; 2014 Nov; 21(6):450-60. PubMed ID: 25299314
[TBL] [Abstract][Full Text] [Related]
18. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
[TBL] [Abstract][Full Text] [Related]
20. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma.
Zhang Q; Xiao Q; Lin Z; Ying X; Li Z; Lin JM
Clin Biochem; 2010 Aug; 43(12):1003-8. PubMed ID: 20444424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
